Close Menu

NEW YORK (GenomeWeb) – Evercore ISI said today that it has initiated coverage of Twist Bioscience with an Outperform rating and a price target of $30.50.

In a note to investors, Evercore ISI Analyst Ross Muken and colleagues wrote that Twist can likely maintain a growth rate of more than 25 percent over the next three to five years through its DNA synthesis and NGS tools businesses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.